Verona Pharma plc (United States)

Verona Pharma is a clinical-stage biopharmaceutical company developing innovative treatments for respiratory diseases. The company created Ohtuvayre (ensifentrine), a first-in-class inhaled dual inhibitor of phosphodiesterase 3 and 4 for COPD maintenance therapy. Verona’s novel approach offers new options for patients with chronic obstructive pulmonary disease.